Sumitomo Chemical
Search results
Sumitomo Pharma defines the practice of its Mission, “To broadly contribute to society through value creation based on innovative research and development activities for the betterment of healthcare and fuller lives of people worldwide,” as Sustainability Management.
About Us. For the betterment of healthcare and fuller lives of people worldwide, we will continue to contribute to the society as a whole, by creating new values based on research and development.
Sumitomo Pharma Company Limited (住友ファーマ株式会社, Sumitomo Fāma Kabushiki-Gaisha) is a Japanese multinational pharmaceutical company. The company is focused on oncology, psychiatry, neurology, women's health issues, urological diseases among other areas.
Dedicated to improving the health and well-being of people around the world. We drive innovative treatments, science, and technology to address patient needs in the critical areas of psychiatry & neurology, oncology, urology, women's health, rare disease, and cell & gene therapy. Learn More.
Mar 31, 2024 · At Sumitomo Pharma, we are focusing our efforts on the research and development of innovative and useful pharmaceuticals as well as healthcare solutions, in the relentless pursuit of our mission: To broadly contribute to society through value creation based on innovative research and development activities for the betterment of healthcare and ...
The Sumitomo Pharma Group aims to fulfill this Mission by delivering innovative, effective pharmaceuticals and healthcare solutions not only to people in Japan but also all over the world...
Strengths 住友ファーマの3つの強み. 1 研究開発力. 2 人材. 3 グローバル基盤. 当社グループは、精神神経領域およびがん領域を重点疾患領域とし、医薬品、再生・細胞医薬、非医薬等による多様なアプローチで人々の健康で豊かな生活に貢献します。. また ...
We are industry-leading experts in drug development, business, engineering, science, and technology. Together, we operate with data-driven insights, agility, and scientific rigor to deliver the therapies that people need most.
Jul 10, 2023 · Sumitomo Pharma America (SMPA) is focused on delivering therapeutic and scientific breakthroughs in areas of critical patient need spanning psychiatry & neurology, oncology, urology, women's health, rare disease, and cell & gene therapies.
Sep 11, 2023 · Sumitomo Pharma Announces Positive Topline Results from Phase 3 Clinical Studies Evaluating Vibegron in Men with Overactive Bladder Symptoms Receiving Pharmacological Therapy for Benign Prostatic Hyperplasia - Sep 11, 2023. Media Contact: Kirsten Fallon CorpComms@us.sumitomo-pharma.com.
